Treatment of mantle cell lymphoma: Current approach and future directions

Joshua Brody, Ranjana Advani

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Although mantle cell lymphoma has been described as "moderately aggressive" it has become clear that it carries a worse long-term prognosis than other subtypes of non-Hodgkin's lymphoma. In recent years, this has prompted numerous clinical trials of novel and more aggressive therapies in hopes of impacting these poor outcomes. These include more intensive combination chemotherapy regimens, monoclonal antibody therapy in conjunction with other treatments or conjugated to radioactive isotopes, high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, and newer targeted therapies based on increasing understanding of the molecular pathways of this malignancy.

Original languageEnglish
Pages (from-to)257-265
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Issue number3
StatePublished - Jun 2006
Externally publishedYes


  • Clinical trials
  • Mantle cell lymphoma
  • Non-Hodgkin's lymphoma


Dive into the research topics of 'Treatment of mantle cell lymphoma: Current approach and future directions'. Together they form a unique fingerprint.

Cite this